Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate efficacy and safety of AMT2003 in cancer patients
with advanced colorectal carcinoma.
The primary endpoint is progression free survival rate at 18 weeks after registration